Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHD HOUSTON, May 4, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering...
Hence then, the article about cellenkos announces fda clearance of investigational new drug ind application for phase 1b 2a trial of ck0802 in steroid refractory graft versus host disease gvhd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD) )
Also on site :
- The Iconic San Francisco Hotel Where Tony Bennett First Left His Heart Turns 119 Today
- Payment Networks Ready Infrastructure for Agentic Commerce at Scale .. PYMNTS.com
- Slate Pears Game 263: May 4, 2026